Jun 15, 2020
Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
Jun 01, 2020
Despite Increased Competition from the Recent Launch of Janssen's Stelara, Takeda's Entyvio Continues to Shine as a Leading Ulcerative Colitis Treatment
May 12, 2020
Ulcerative Colitis Market Report 2020: Pipeline, Epidemiology, Competitive Analysis, Drug Sales and Shares through 2016-2024
May 07, 2020
Novel Real-World Data Findings From Ongoing TARGET-IBD Study Published In DDW Proceedings
May 07, 2020
InDex Pharmaceuticals Holding AB (publ) Interim Report January - March 2020
Apr 20, 2020
Theravance Biopharma Announces Peer-Reviewed Publication Highlighting TD-1473 Program in the Journal of Crohn's and Colitis
Apr 16, 2020
InDex Pharmaceuticals Advances Cobitolimod Further Towards Phase III Following Successful Interactions With FDA and EMA
Apr 09, 2020
Crohn's & Colitis Foundation Welcomes New National Trustees
Apr 09, 2020
Bridge Biotherapeutics Discloses Interim Results from the First Cohort of Phase 2a Study of BBT-401, an Experimental Drug for Ulcerative Colitis
Mar 31, 2020
InDex Pharmaceuticals Receives Grant From Vinnova for Pre-clinical Development of DIMS Compounds in Inflammation
Feb 25, 2020
Connect Biopharma Enhances its Intellectual Property Estate for CBP-307, a Targeted Therapy with Potential in Multiple Autoimmune Diseases, with Patent Issuances in the United States, EU, Japan and Australia
Feb 25, 2020
InDex Pharmaceuticals Publishes Mechanism of Action Data for Cobitolimod in Scientific Journal
Feb 19, 2020
InDex Pharmaceuticals' In-depth Analysis of the CONDUCT Study Confirms the Successful Top Line Results and Supports the Strategy Going Forward
Feb 07, 2020
Protagonist Therapeutics to Present Preclinical Results on PN-943 at the 15th Congress of European Crohn's and Colitis Organization (ECCO)
Jan 30, 2020
Genedata and the Crohn's & Colitis Foundation Collaborate to Improve Patient Care in Crohn's Disease
Jan 15, 2020
NuMedii, Inc. Announces Pharmaceutical Discovery Collaboration For Ulcerative Colitis
Jan 07, 2020
Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration
Dec 26, 2019
Bridge Biotherapeutics Announces China NMPA Clearance of IND for BBT-401, a Pellino-1 Inhibitor for UC
Dec 04, 2019
Immunic, Inc. to Present Data on IMU-856, for the First Time, at the Crohn's and Colitis Foundation's IBD Innovate Conference
Nov 25, 2019
Immunic, Inc. to Participate in Investor and Scientific Conferences in December